Recurrent and de novo disease after renal transplantation: a report from the Renal Allograft Disease Registry.
Recurrent and de novo disease is an increasing problem and is known to negatively impact transplant graft survival. Immunosuppressive medications have not had an impact on the prevalence of recurrent and de novo disease. Renal Allograft Disease Registry (RADR) was established to study the prevalence, impact and risk factors for the development of recurrent and de novo disease. Retrospective and prospective study on recurrent disease is discussed in this manuscript.
Hariharan
Sundaram
S
Division of Nephrology, Medical College of Wisconsin, 9200 West Wisconsin Avenue, Milwaukee, WI 53226, USA. hari@mcw.edu
Savin
Virginia J
VJ
D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D005500:Follow-Up Studies; D006801:Humans; D016030:Kidney Transplantation; D015337:Multicenter Studies as Topic; D011446:Prospective Studies; D012008:Recurrence; D012042:Registries / Q000706:statistics & numerical data*; D012189:Retrospective Studies; D014184:Transplantation, Homologous